AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Foghorn Therapeutics Inc (NASDAQ:FHTX)
4.92 USD
+0.020 0.408%| Previous Close (in USD) | 4.9 |
|---|---|
| Change | +0.020 0.408% |
| 52 W H/L (in USD) | 9.970/2.700 |
| EBITDA (in USD) | -99.356M |
| PE Ratio | -- |
| Volume | 13689 |
| Diluted Eps TTM | -2.20 |
| Total Assets (in USD) | 285.916M |
|---|---|
| Total Liabilities (in USD) | 363.106M |
| Revenue TTM (in USD) | 33.896M |
| Cash (in USD) | 80.336M |
| Market Cap (in USD) | 312.054 M |
| Revenue Per Share TTM | 0.805 |
| Gross Profit TTM (in USD) | -86.39M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Employees: 116
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Adrian H. B. Gottschalk | Pres, CEO & Director | 1976 |
| 2. | Dr. Allan Reine M.D. | Chief Financial Officer | 1975 |
| 3. | Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer | 1973 |
| 4. | Dr. Gerald R. Crabtree M.d. | Founder & Member of Scientific Advisory Board | NA |
| 5. | Dr. Steven F. Bellon Ph.D. | Chief Scientific Officer | 1965 |
| 6. | Mr. Ben Strain | VP of Investor Relations & Corp. Communications | NA |
| 7. | Mr. Michael J. LaCascia | Chief Legal Officer | 1965 |
| 8. | Mr. Saurabh Sewak Ph.D. | VP of Corp. Devel. | NA |
| 9. | Mr. Carlos Costa | Chief People Officer | NA |
| 10. | Ms. Fanny Cavalie | Chief Strategy & Bus. Operations Officer | 1978 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.140 0.208% | 67.62 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.510 0.756% | 68.9 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-3.525 0.791% | 445.82 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-0.870 0.167% | 520 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -108.882M | -101.32M | -68.8M | -51.128M | -26.337M |
| Minority Interest | - | - | - | - | - |
| Net Income | -108.874M | -103.226M | -69.779M | -51.668M | -26.337M |
| Selling General Administrative | 30.747M | 21.728M | 11.246M | 6.722M | 4.824M |
| Gross Profit | 19.209M | 1.319M | 0.43M | - | - |
| Reconciled Depreciation | 3.321M | 3.227M | 1.327M | 0.693M | 0.379M |
| Ebit | -120.458M | -100.734M | -68.531M | -51.084M | -25.936M |
| Ebitda | -117.137M | -94.954M | -66.203M | -49.896M | -25.557M |
| Depreciation And Amortization | 3.321M | 5.78M | 2.328M | 1.188M | 0.379M |
| Operating Income | -117.137M | -100.734M | -68.531M | -51.084M | -26.049M |
| Other Operating Expenses | 136.365M | 102.053M | 68.961M | 51.084M | 26.049M |
| Interest Expense | 11.568M | 1.906M | 0.979M | 0.54M | 0.371M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 5.675M | 2.553M | 1.001M | 0.495M | 0.113M |
| Net Interest Income | 5.675M | 0.647M | 0.022M | -0.045M | -0.258M |
| Income Tax Expense | -0.008M | 1.906M | 0.979M | 0.54M | 0.083M |
| Total Revenue | 19.228M | 1.319M | 0.43M | 0M | 0M |
| Total Operating Expenses | 136.365M | 102.053M | 68.961M | 51.084M | 26.049M |
| Cost Of Revenue | 0.019M | 0.001M | - | - | - |
| Total Other Income Expense Net | 8.255M | -0.586M | -0.269M | -0.044M | -0.03M |
| Net Income From Continuing Ops | -108.882M | -101.32M | -68.8M | -51.128M | -26.337M |
| Net Income Applicable To Common Shares | -108.882M | -101.32M | -68.8M | -51.128M | -26.337M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 285.916M | 404.883M | 519.774M | 255.594M | 22.342M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 6.124M | 5.601M | 5.273M | 4.917M | 1.363M |
| Total Liab | 363.106M | 404.771M | 422.903M | 109.407M | 110.358M |
| Total Stockholder Equity | -77.19M | 0.112M | 96.871M | 146.187M | -88.016M |
| Other Current Liab | 9.108M | -11.384M | 9.562M | 9.161M | 0.45M |
| Common Stock | 0.004M | 0.004M | 0.004M | 0.004M | 0.001M |
| Capital Stock | 0.004M | 0.004M | 0.004M | 0.004M | 0M |
| Retained Earnings | -471.564M | -373.138M | -264.256M | -162.936M | -94.136M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 4.087M | 4.133M | 2.575M | 1.744M |
| Cash | 80.336M | 345.798M | 101.136M | 92.795M | 14.981M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 58.436M | 336.82M | 48.692M | 18.846M | 12.652M |
| Current Deferred Revenue | 34.55M | 336.82M | 28.317M | 2.024M | 3.251M |
| Net Debt | -35.263M | -294.291M | -42.804M | -10.799M | 1.648M |
| Short Term Debt | 8.518M | 5.97M | 6.994M | 3.981M | 5.512M |
| Short Long Term Debt | - | - | - | - | 4.152M |
| Short Long Term Debt Total | 45.073M | 51.507M | 58.332M | 81.996M | 16.629M |
| Other Stockholder Equity | 395.196M | 377.232M | 361.133M | 53.532M | 6.12M |
| Property Plant Equipment | - | 49.397M | 56.079M | 62.332M | 3.713M |
| Total Current Assets | 240.181M | 345.798M | 459.562M | 190.687M | 16.885M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 153.721M | 293.584M | 53.153M | 92.975M | - |
| Net Receivables | - | 2.379M | 300M | 0.842M | - |
| Long Term Debt | - | - | - | 19.654M | 10.96M |
| Inventory | - | - | -353.153M | - | - |
| Accounts Payable | 6.26M | 5.414M | 3.819M | 3.68M | 3.439M |
| Accumulated Other Comprehensive Income | -0.826M | -3.986M | -0.01M | -0.007M | -1.292M |
| Non Currrent Assets Other | 1.115M | 9.688M | 4.133M | 2.575M | 1.744M |
| Non Current Assets Total | 45.735M | 59.085M | 60.212M | 64.907M | 5.457M |
| Capital Lease Obligations | 45.073M | 51.507M | 58.332M | 62.342M | 1.517M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -243.112M | 39.486M | -108.914M | -0.964M | -1.541M |
| Total Cashflows From Investing Activities | -244.322M | 36.173M | -108.914M | -0.964M | -1.541M |
| Total Cash From Financing Activities | 1.763M | 22.418M | 217.473M | 23.969M | 51.77M |
| Net Income | -108.882M | -101.32M | -68.8M | -51.128M | -26.337M |
| Change In Cash | -48.947M | 8.341M | 77.273M | -23.33M | 27.581M |
| Begin Period Cash Flow | 102.869M | 94.528M | 17.255M | 40.585M | 13.004M |
| End Period Cash Flow | 53.922M | 102.869M | 94.528M | 17.255M | 40.585M |
| Total Cash From Operating Activities | 193.612M | -50.25M | -31.286M | -46.335M | -22.648M |
| Depreciation | 3.321M | 3.227M | 1.327M | 0.693M | 0.379M |
| Other Cashflows From Investing Activities | - | - | 0.25M | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | -3.171M | - | - | - |
| Sale Purchase Of Stock | 1.763M | 43.623M | 123.342M | - | - |
| Other Cashflows From Financing Activities | -244.322M | 1.418M | 110.882M | -0.964M | 52.593M |
| Capital Expenditures | 1.21M | 3.313M | 16.183M | 0.968M | 1.541M |
| Change In Working Capital | 281.546M | 33.441M | 28.703M | 1.197M | 2.424M |
| Other Non Cash Items | 3.291M | 4.606M | 4.439M | 1.199M | 0.124M |
| Free Cash Flow | 192.402M | -53.563M | -47.469M | -47.303M | -24.189M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Growth Compy Commingled Pl O | 1 year ago | 1287533 |
| 2. | Fidelity Growth Company Fund | 1 year ago | 927482 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 597869 |
| 4. | iShares Russell 2000 ETF | 1 year ago | 470120 |
| 5. | Fidelity Growth Company K6 | 1 year ago | 293323 |
| 6. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 286260 |
| 7. | Fidelity Small Cap Index | 1 year ago | 209057 |
| 8. | Fidelity Series Growth Company | 1 year ago | 181383 |
| 9. | iShares Russell 2000 Growth ETF | 1 year ago | 176797 |
| 10. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 138693 |
| 11. | Fidelity Extended Market Index | 1 year ago | 113220 |
| 12. | Vanguard Russell 2000 ETF | 1 year ago | 75162 |
| 13. | State St Russell Sm Cap® Indx SL Cl I | 1 year ago | 74899 |
| 14. | Vanguard Health Care ETF | 1 year ago | 61935 |
| 15. | NT R2000 Growth Index Fund - NL | 1 year ago | 60986 |
| 16. | NT R2000 Index Fund - NL | 1 year ago | 58492 |
| 17. | Invesco Russell 2000® Dynamic Mltfct ETF | 1 year ago | 47317 |
| 18. | NT R2000 Index Fund - DC - NL - 2 | 1 year ago | 46487 |
| 19. | Schwab Small Cap Index | 1 year ago | 46468 |
| 20. | NT R2000 Growth Index Fund - L | 1 year ago | 46198 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Flagship Ventures Management, Inc. | 1 year ago | 12674120 |
| 2. | FMR Inc | 1 year ago | 2810009 |
| 3. | Raymond James & Associates | 1 year ago | 2068387 |
| 4. | Euclidean Capital LLC | 1 year ago | 1573761 |
| 5. | BlackRock Inc | 1 year ago | 1305868 |
| 6. | Vanguard Group Inc | 1 year ago | 1102493 |
| 7. | Artal Group S A | 1 year ago | 720720 |
| 8. | Alphabet Inc | 1 year ago | 500901 |
| 9. | Geode Capital Management, LLC | 1 year ago | 448350 |
| 10. | State Street Corporation | 1 year ago | 422630 |
| 11. | Birchview Capital, LP | 1 year ago | 320930 |
| 12. | Driehaus Capital Management LLC | 1 year ago | 280382 |
| 13. | Jacobs Levy Equity Management, Inc. | 1 year ago | 216270 |
| 14. | Northern Trust Corp | 1 year ago | 199274 |
| 15. | Sio Capital Management, LLC | 1 year ago | 121672 |
| 16. | Morgan Stanley - Brokerage Accounts | 1 year ago | 105113 |
| 17. | Panagora Asset Management Inc | 1 year ago | 100305 |
| 18. | Millennium Management LLC | 1 year ago | 62047 |
| 19. | Bank of New York Mellon Corp | 1 year ago | 57198 |
| 20. | Charles Schwab Investment Management Inc | 1 year ago | 55442 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...